185 related articles for article (PubMed ID: 28145609)
61. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
[TBL] [Abstract][Full Text] [Related]
62. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
Chen SL; Sheiban I; Xu B; Jepson N; Paiboon C; Zhang JJ; Ye F; Sansoto T; Kwan TW; Lee M; Han YL; Lv SZ; Wen SY; Zhang Q; Wang HC; Jiang TM; Wang Y; Chen LL; Tian NL; Cao F; Qiu CG; Zhang YJ; Leon MB
JACC Cardiovasc Interv; 2014 Nov; 7(11):1266-76. PubMed ID: 25326748
[TBL] [Abstract][Full Text] [Related]
63. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
[TBL] [Abstract][Full Text] [Related]
64. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
[TBL] [Abstract][Full Text] [Related]
65. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
66. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).
Shah B; Baber U; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28916600
[TBL] [Abstract][Full Text] [Related]
67. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
68. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
Kukreja N; Onuma Y; Garcia-Garcia HM; Daemen J; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2009 Jun; 2(6):534-41. PubMed ID: 19539258
[TBL] [Abstract][Full Text] [Related]
69. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
[TBL] [Abstract][Full Text] [Related]
70. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
71. The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent.
Nardin M; Pivato CA; Cao D; Sartori S; Zhang Z; Vogel B; Nicolas J; Chiarito M; Qiu H; Chandrasekhar J; Spirito A; Abizaid A; Christiansen EH; Colombo A; de Winter RJ; Haude M; Jakobsen L; Jensen LO; Krucoff MW; Landmesser U; Saito S; Suryapranata H; De Luca G; Dangas G; Mehran R
Int J Cardiol; 2023 Jan; 370():149-155. PubMed ID: 36270496
[TBL] [Abstract][Full Text] [Related]
72. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
73. Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial.
Jensen LO; Thayssen P; Maeng M; Christiansen EH; Ravkilde J; Hansen KN; Kaltoft A; Tilsted HH; Madsen M; Lassen JF;
JACC Cardiovasc Interv; 2014 Aug; 7(8):840-8. PubMed ID: 25086842
[TBL] [Abstract][Full Text] [Related]
74. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
75. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
76. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
77. One-year follow-up of patients treated with new-generation polymer-based 38 mm everolimus-eluting stent: the P38 study.
Sgueglia GA; Belloni F; Summaria F; Conte M; Cortese B; Silva PL; Ricci R; Lioy E; Pucci E; Gaspardone A
Catheter Cardiovasc Interv; 2015 Feb; 85(2):218-24. PubMed ID: 24824088
[TBL] [Abstract][Full Text] [Related]
78. Safety and efficacy of self-apposing Stentys drug-eluting stent in left main coronary artery PCI: Multicentre LM-STENTYS registry.
Wańha W; Mielczarek M; Smolka G; Roleder T; Jaguszewski M; Ciećwierz D; Tomasiewicz B; Kubler P; Gorol J; Chmielecki M; Bartuś S; Navarese EP; Kasprzak M; Sukiennik A; Kubica J; Lekston A; Hawranek M; Reczuch K; Gruchała M; Ochała A; Wojakowski W
Catheter Cardiovasc Interv; 2019 Mar; 93(4):574-582. PubMed ID: 30311397
[TBL] [Abstract][Full Text] [Related]
79. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
[TBL] [Abstract][Full Text] [Related]
80. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
